BUZY PETER L 4/A
4/A · Catalent, Inc. · Filed Oct 23, 2019
Insider Transaction Report
Form 4/AAmended
Catalent, Inc.CTLT
BUZY PETER L
President, Gene Therapy
Transactions
- Award
Options to purchase Common Stock
2019-05-17+231,700→ 231,700 totalExercise: $0.87From: 2019-05-17Exp: 2024-12-16→ Common Stock (231,700 underlying)
Footnotes (1)
- [F1]Options to purchase common stock received by the reporting person under the Issuer's omnibus incentive plan in connection with the assumption of certain vested, in-the-money options held by reporting person under the incentive plan of Paragon Bioservices, Inc. coincident with that entity's acquisition by one of Issuer's subsidiaries. As reported in the Form 4 filed by the reporting person on May 21, 2019 that this Form 4/A is amending, the number of options and the exercise price thereof (originally 230,093 and $0.88, respectively) were subject to adjustment based on post-closing net purchase price adjustments. Those adjustments have resulted in additional value accruing to the reporting person, as reflected in the options' amended quantity and exercise price.